A Textbook Operating Quarter the Market Shrugged Off: Keytruda Tops $8B and the Guide Rises, But a Pipeline Failure and Serial Dealmaking Keep Us Sidelined

Results vs. Consensus

Year-over-Year Comparison (Q1'26 vs. Q1'25)

Sequential Comparison (Q1'26 vs. Q4'25)

The sequential picture is cleaner than the loss suggests: gross margin recovered 220 bps toward the guided ~82%, the Qlex conversion nearly quadrupled off a tiny base, and revenue held roughly flat against a seasonally strong Q4. The reported loss is the Cidara charge and nothing else.

Quality of Beat/Miss

• Revenue: High quality but with a timing flatter. The beat was demand-led across oncology, cardiopulmonary, and Animal Health, with a ~1 point FX tailwind. Management disclosed ~$250M of Keytruda US purchase timing that helped Q1 and hurts Q3, so normalize the oncology line accordingly.
• Margins: Solid. Non-GAAP gross margin of 81.9% is essentially flat YoY and up sharply from Q4's 79.7%, tracking the guided ~82% recovery. Operating expenses ex-Cidara grew only 2%, helped by the optimization program and recognition of external sac-TMT funding.
• EPS: The headline is meaningless in isolation. The -$1.28 non-GAAP loss is entirely the $3.62 Cidara charge; ex-charge underlying EPS of ~$2.34 is the number that matters, and it grew versus $2.22 a year ago. The negative tax rate (-43.5%) is a mechanical artifact of the non-deductible charge.

Segment Performance

Oncology (Keytruda crosses $8B; a pipeline setback appears)

Keytruda grew 8% ex-FX (12% nominal) to $8.03B, comfortably ahead of the ~$7.7B consensus, powered by metastatic demand and earlier-stage uptake in women's cancers (breast, cervical) and renal cell carcinoma. The subcutaneous Qlex ramped to $128M and received its permanent J-code on April 1, the reimbursement unlock we flagged last quarter. Beyond Keytruda, Welireg grew 43% to $199M and the FDA/EC approved Keytruda in platinum-resistant ovarian cancer (KEYNOTE-B96). The blemish came from Welireg's LITESPARK-012 study, which missed its dual progression-free and overall-survival endpoints in first-line kidney cancer.

"The combination regimens from the LITESPARK-012 study did not meet the dual primary end point of progression-free survival and overall survival for the first-line treatment of patients with RCC... The data from the study provides learnings to the broader program." — Dr. Dean Li, President, Merck Research Laboratories

Assessment: The core Keytruda beat and the Qlex J-code are exactly what the bull case needed, and the ovarian approval widens the moat. But LITESPARK-012 is the first tangible reminder this quarter that the pipeline that has to replace Keytruda will not convert in a straight line. Management argues it has no read-through to the June and October WELIREG PDUFAs; we would treat that as plausible but unproven.

Cardiometabolic & Respiratory (the growth engine keeps compounding)

Winrevair (PAH)

Winrevair remains the standout, up 87% ex-FX to $525M, with more than 1,600 new US patients started in the quarter. Full CADENCE Phase 2 data at ACC met the primary endpoint (pulmonary vascular resistance reduction) in the harder-to-treat HFpEF-associated pulmonary-hypertension population, with a striking 0.18 hazard ratio on time to clinical worsening (an exploratory endpoint), supporting a move to Phase 3 in a setting with no approved therapies.

"Winrevair... is reshaping the standard of care in PAH. And now the question is whether or not we can move it to a different segment of pulmonary hypertension, those people with heart disease... it's probably one of the biggest unmet needs that I know of." — Dr. Dean Li, President, MRL

Ohtuvayre (COPD) and Enlicitide

Ohtuvayre generated $131M but was held back by a CMS reimbursement change and Medicare deductible resets, with prescriptions recovering in March and a second-half acceleration expected. Enlicitide, the oral PCSK9 inhibitor, posted positive CORALreef Add-on data at ACC and remains on track for a potential second-half approval.

Assessment: This is the part of the story doing the heavy lifting for the post-Keytruda thesis. Winrevair's HFpEF proof-of-concept is genuinely important because it expands the addressable population well beyond PAH, and enlicitide is one of the most tangible near-term pillars of the $70B. These franchises are why the pipeline setback in oncology did not change our overall read.

Vaccines & Infectious Disease (Gardasil bleeds, HIV re-enters)

Gardasil fell 22% ex-FX to $1.07B, with China down 47% and continued weakness in Japan and the US; it modestly beat a low bar. Capvaxive grew 31% to $142M. The clear positive was the FDA approval of IDVYNSO, the doravirine/islatravir two-drug regimen and the first HIV two-drug regimen without an integrase inhibitor, delivering on last quarter's April PDUFA commitment.

"IDVYNSO is the first approved 2-drug regimen that does not include an integrase strand transfer inhibitor." — Dr. Dean Li, President, MRL

Assessment: Gardasil has effectively become a melting ice cube in its two biggest ex-US markets, and investors should carry it in the model as a structural headwind, not a recovery story. IDVYNSO gives Merck a genuine non-oncology growth pillar and validates the islatravir platform, whose real prize is the weekly and monthly regimens still in development.

Animal Health (still the ballast)

Animal Health grew 6% ex-FX (13% nominal) to $1.79B, with livestock up 8% and companion animal returning to growth (+4%) on new launches including NUMELVI, the first second-generation JAK inhibitor for canine allergic dermatitis.

Assessment: Consistent, high-quality, and uncorrelated to the Keytruda cliff. The companion-animal return to growth is a small but welcome inflection. This segment remains underappreciated in the sum-of-the-parts.

Key Topics & Management Commentary

Overall Management Tone: Confident and execution-focused, leaning hard into the breadth of near-term catalysts and the portfolio transformation while treating the LITESPARK-012 failure and the charge-laden P&L as manageable noise. Management was most assured on Keytruda's momentum, Winrevair's expansion, and business-development discipline, and most careful when parsing a Phase 3 failure's read-through and the exact profile of newly acquired assets. Versus the defensive-tinged Q4 call, the posture this quarter was more forward-leaning, anchored on a dense run of 2026 regulatory decisions.

1. Keytruda Momentum and the Qlex Conversion

Keytruda's $8.0B quarter and the Qlex ramp to $128M with the April 1 J-code were the operational centerpiece. Management reiterated that Keytruda now spans 44 FDA-approved indications and continues to expand into earlier-stage settings, while positioning Qlex as the primary defense against biosimilar erosion.

"Sales of the Keytruda family of products... increased 8% to $8 billion... We are pleased with the positive feedback following the recent launch of Keytruda Qlex. Sales in the quarter were $128 million. On April the 1st, we received the permanent J code." — Caroline Litchfield, CFO

Assessment: The J-code and the near-quadrupling of Qlex are concrete progress on the single most important assumption in the model. It is early, but the conversion machine is now switched on, and the 30–40% by-2028 target is looking incrementally more credible than it did a quarter ago.

2. The LITESPARK-012 Failure and Pipeline Read-Through

The WELIREG first-line RCC failure prompted the sharpest analytical exchange of the call. Management drew a firm line between the three-drug LITESPARK-012 regimen and the upcoming two-drug WELIREG combinations with June and October PDUFA dates, arguing the failure does not read through.

"I would be very cautious to sit there and say that has any negative implication to other trials where, for example, we have a VEGF TKI and WELIREG or a PD-1 and WELIREG." — Dr. Dean Li, President, MRL

Assessment: The mechanistic argument for no read-through is reasonable, but a Phase 3 miss is a Phase 3 miss, and it lands squarely on the pillar that must carry the post-2028 story. This is the quarter's most important watch item; the June 19 adjuvant-RCC PDUFA is the next real test.

3. The Terns Acquisition and Serial Dealmaking

Merck announced a tender offer for Terns Pharmaceuticals and its oral BCR::ABL inhibitor TERN-701 for chronic myeloid leukemia, framing it as multibillion-dollar potential and a disciplined, science-led bolt-on. It follows Cidara and Verona, and adds a ~$5.8B (~$2.35/share) one-time charge on close.

"TERN-701 has the potential to be a best-in-class therapy... we believe TERN-701 has multibillion-dollar commercial potential and will be a significant driver of growth in the next decade." — Rob Davis, Chairman & CEO

Assessment: Individually sensible and on-strategy, but the cadence of upfront-charge deals is turning the reported P&L into a moving target and pushing net debt toward ~$50B. The strategy is defensible; the optics and the balance-sheet trajectory now warrant closer monitoring, and the pointed Q&A on TERN-701's response rates shows the Street is scrutinizing what each deal actually buys.

4. Business-Development Framework and Capacity

Asked where the remaining portfolio gaps are and whether BD urgency fades as the pipeline matures, management held to its science-first, value-disciplined framework, naming oncology, immunology, and cardiometabolic as the most likely areas and a $1–15B "sweet spot" with capacity to go bigger.

"We start with the science... We continue to look anywhere in the $1 billion to $15 billion range with that kind of being the sweet spot. But... we have the capacity to go beyond that for the right strategic deal... My view is we can always do better." — Rob Davis, Chairman & CEO

Assessment: The "we can always do better" posture confirms BD will remain a constant, which is both the source of the pipeline's optionality and the source of the balance-sheet and dilution risk. With the stock off its highs, the willingness to "go bigger" is the biggest wildcard to the ~$3B buyback and capital-return story.

5. Winrevair's HFpEF Expansion (CADENCE)

Management framed the CADENCE proof-of-concept as opening a large, wholly unserved population and is in active FDA discussions on the Phase 3 design and endpoints, emphasizing time-to-clinical-worsening over the PVR primary.

"It's fine to talk about the primary endpoint reductions in PVR. But... in this patient population, it will be very important to have the endpoints that allow... patients, providers and payers to really see a compelling conglomerate of endpoints in the time to clinical worsening." — Dr. Dean Li, President, MRL

Assessment: If a Phase 3 confirms the CADENCE signal, Winrevair's addressable market expands materially beyond PAH into a far larger cardiopulmonary population. This is one of the higher-conviction internal expansion opportunities in the portfolio and a genuine offset to the oncology setback.

6. sac-TMT (TROP2 ADC) and the ASCO Setup

With a competitor's PD-1/VEGF data due at ASCO, management addressed how it is positioning sac-TMT (now 17 Phase 3 studies, 13 first-mover) and its own PD-1/VEGF asset, flagging the partner Kelun's OptiTROP first-line lung data as an important early read for its global program.

"We have 17 Phase III studies, 13 are in first movers... this is the first Phase III combination study of sac-TMT and Keytruda to read out. We have 50% of our Trop studies... evaluating Keytruda combos." — Dr. Dean Li, President, MRL

Assessment: sac-TMT is one of the largest swing factors inside the $70B, and the program keeps expanding. The June 1 ASCO investor event and the Kelun OptiTROP readout are the near-term data points that will shape how much credit the Street gives it.

7. HIV Strategy and Competitive Setup

Following IDVYNSO's approval and against an intensifying long-acting competitive backdrop, management underscored deep commitment to HIV across daily, weekly (islatravir plus Gilead's lenacapavir), and monthly PrEP candidates.

"Of the 2-drug daily programs, I think we're the only ones without an integrase backbone... critically also important is that we believe islatravir can anchor to weekly... if the question is, are we committed and passionate about our HIV program, the answer is unequivocally yes." — Dr. Dean Li, President, MRL

Assessment: The integrase-sparing daily regimen is a real differentiator, but the strategic prize is weekly and monthly dosing where the ISLEND readouts this year matter most. HIV is re-emerging as a credible, durable non-oncology franchise.

8. TL1A (Tulisokibart) and Immunology Depth

On its TL1A inhibitor, management again framed the class as a potential third inflammation node, previewed ulcerative-colitis and Crohn's readouts, and hinted at combination and fibrosis optionality, with the CEO teasing undisclosed "invisible pipeline" immunology assets.

"We aren't just a TL1A company. We have other things in development beyond that. And as we move forward in time, you'll start to get a better sense of that as we unleash that as it moves into Phase I." — Rob Davis, Chairman & CEO

Assessment: Immunology is a large, durable diversification vector, and the ATLAS-UC readout this year is the gating event. The "invisible pipeline" tease is a reminder that the disclosed $70B may understate the internal optionality, though it is not yet investable.

9. Commercial Reorganization and AI Partnerships

Management announced a shift to a therapeutic-area business-unit model with new leadership, alongside a multiyear Google Cloud partnership and expanded Tempus AI and Mayo Clinic collaborations, positioning both as execution accelerants for the 20-plus launches underway.

"Our new business unit model, organized around products in therapeutic areas is built to drive accountability, sharpen focus and increase agility, ensuring that every part of our commercial organization delivers on the promise of our pipeline." — Rob Davis, Chairman & CEO

Assessment: Reorganizing the commercial engine mid-transition carries some execution risk, but aligning it around the coming wave of launches is logical. The AI partnerships are sensible productivity plays; we would not underwrite quantified benefit yet.

10. Gardasil and the Vaccine Overhang

Gardasil's 22% ex-FX decline, with China down 47%, was described as consistent with expectations, and management pointed to US CDC purchase timing rather than underlying demand for the domestic softness.

"Gardasil sales were $1.1 billion, a decrease of 22%, driven by lower demand in China and Japan, consistent with our expectations. In the U.S., sales declined 10%, primarily due to timing of CDC purchases." — Caroline Litchfield, CFO

Assessment: "Consistent with expectations" is doing a lot of work; the China business is effectively gone and the model should treat it that way. Vaccines will remain a drag, and the single-dose HPV schedule change adds further downside risk to the US line.

Guidance & Outlook

Management narrowed and raised both revenue and EPS, lifting the revenue floor to $65.8B (from $65.5B) and the EPS midpoint to $5.10 (from $5.08), helped by underlying strength and an FX tailwind. The reported EPS guide still includes the $3.62 Cidara charge and, critically, still excludes the pending Terns acquisition, which on close (expected May) will add another ~$5.8B (~$2.35/share) one-time charge plus ~$0.12/share of ongoing carry. Clean of both one-time charges, the underlying 2026 EPS run-rate sits around $8.7–9.0, roughly flat against 2025's $8.98.

Implied ramp: The raise is modest, and management flagged a Q3 Keytruda headwind (the reversal of the ~$250M Q1 purchase timing), minimal Enflonsia in Q2 before a second-half RSV-season ramp, and rising SG&A through the year. The full-year shape is back-half-weighted on launches.

Street at: Consensus revenue should settle near the raised midpoint (~$66.4B), still below the ~$67.6B the Street modeled pre-2026. Reported EPS estimates will need another downward reset once Terns closes and its charge lands; underlying ex-charge EPS estimates hold near $9.

Guidance style: Consistent with Merck's conservative-and-raise pattern. Raising in Q1 rather than simply reaffirming is a mild positive, but the raise is small enough that management is clearly preserving room for the back half.

Analyst Q&A Highlights

WELIREG LITESPARK-012 Read-Through

The most probing exchange asked whether the first-line RCC failure signals risk to the upcoming WELIREG readouts. Management restated the question through poor audio and drew a clear distinction between the failed three-drug regimen and the two-drug combinations awaiting PDUFA decisions.

Q: "Does this provide any concerning read-through to some of the ongoing readouts for LITESPARK-022 and the ability to see OS benefit there?... just kind of curious if you can speak to some of the read-throughs to some of the ongoing trials."
— Jason Gerberry, Bank of America

A: "In relationship to the other ones like LITESPARK-022, LITESPARK-011, which have PDUFA date in June and October... I think we're very bullish in relationship to how those will turn out... I would be very cautious to sit there and say that has any negative implication to other trials."
— Dr. Dean Li, President, MRL

Assessment: Management's confidence is mechanistically defensible but self-interested; the June 19 adjuvant-RCC PDUFA is the near-term proof point. Until then, the market is right to dock the pipeline pillar slightly.

Business Development Gaps and Deal Size

A high-level question asked where the remaining portfolio gaps are, whether the deal-size sweet spot has changed, and whether BD urgency diminishes as organic confidence grows. Management gave its clearest articulation of the framework and its persistence.

Q: "Where do you still see the biggest gaps in your portfolio that could benefit from more BD... What's the sweet spot now in terms of deal size? And is there a point at which the BD lever starts to diminish in importance?"
— Asad Haider, Goldman Sachs

A: "We continue to look anywhere in the $1 billion to $15 billion range with that kind of being the sweet spot. But... we have the capacity to go beyond that for the right strategic deal... My view is we can always do better. We can always grow stronger. And if we have the capacity, we will continue to invest."
— Rob Davis, Chairman & CEO

Assessment: The answer confirms serial dealmaking is structural, not opportunistic. That is the engine of the pipeline optionality and, simultaneously, the primary risk to the balance sheet and capital-return story.

Terns / TERN-701 Response-Rate Scrutiny

A pointed question challenged the durability of TERN-701's efficacy, suggesting incremental patient data implied a much lower molecular-response rate. Management pushed back, walking through how it re-underwrites congress data to a conservative intent-to-treat basis.

Q: "By my math, it looks like the incremental patients may have had an MMR achievement rate of something like 2 out of 10... Could you just speak to that drop and how does that change or not change your overall thoughts about the drug's profile?"
— Umer Raffat, Evercore ISI

A: "What was laid out at these public congresses is Terns stated a 75% MMR and 36% DMR achievement rate. As the data evolved and we were looking at very specific patient-level data, we believe that the MMR will be north of 50%... we think that in MMR in that sort of range is extremely compelling." — Dr. Dean Li, President, MRL

Assessment: The exchange shows healthy Street skepticism about what each acquisition actually buys. Management's "north of 50% MMR" is still a strong CML profile, but the gap versus the headline 75% is a reminder to discount acquired-asset marketing.

sac-TMT Positioning Into ASCO

With competitor PD-1/VEGF data due at ASCO, questioning sought Merck's stance on sac-TMT, its own PD-1/VEGF asset, and potential combinations. Management confirmed active interest in combining modalities and flagged the partner readout as an important tell.

Q: "How are you thinking about the dynamic of sac-TMT in the context of PD-1 VEGFs and your own... asset and perhaps accelerating that?"
— Michael Yee, UBS

A: "We're very interested in the space... if a PD-1 VEGF should be better than Keytruda, we have a plethora of agents that would benefit from a combination... In relationship to the question... is there any possibility of thinking about combining those, the answer is absolutely yes."
— Dr. Dean Li, President, MRL

Assessment: Management is keeping optionality open across modalities rather than committing, which is prudent given the fast-moving competitive field. The June ASCO event is where the sac-TMT narrative gets re-rated up or down.

Winrevair HFpEF Phase 3 Design and Timing

A question sought detail on FDA discussions for the next-segment Winrevair program and the likely trial duration. Management emphasized endpoint selection and inclusion criteria in an orphan population.

Q: "Any updated thoughts on how the discussions with the FDA are going on moving forward the Phase II program... and any rough estimate on how long you think you would actually take to execute a Phase III program in this indication?"
— Vamil Divan, Guggenheim Securities

A: "The cadence gives that proof of concept... it will be very important to have the endpoints that allow... patients, providers and payers to really see a compelling conglomerate of endpoints in the time to clinical worsening... in our minds, this is a patient population that is an orphan patient population."
— Dr. Dean Li, President, MRL

Assessment: Management is signaling a rigorous, endpoint-driven Phase 3 rather than a fast follow, which lowers near-term catalyst value but raises the odds of a clean approval in a genuinely unserved market.

MK-3000 Dosing Durability

The opening question challenged whether MK-3000's retinal-disease profile can hit commercial targets if it requires frequent dosing. Management confirmed the initial four-week label focus while keeping longer intervals in play.

Q: "I fully appreciate that 40% have suboptimal responses to VEGF, but can this reach your targets if it ultimately requires every 4-week dosing? Or... are there reasons you have conviction about every week or every 12-week dosing?"
— Carter Gould, Cantor Fitzgerald

A: "We believe that one should focus on Q4 weeks, but one should not only focus on Q4 weeks... the initial focus is on 4 weeks because that is very important to get into the label." — Dr. Dean Li, President, MRL

Assessment: Dosing durability is the swing variable for MK-3000's commercial ceiling. Management is sequencing the label conservatively, so the BRUNELLO data will inform efficacy more than the ultimate dosing-interval opportunity.

TL1A Role in IBD and Combinations

A question explored TL1A's place in an increasingly combination-oriented IBD market. Management framed tulisokibart as a potential first-and-best-in-class node with a favorable tolerability profile and clear combination ambitions.

Q: "Can you just talk a little bit about the role you're seeing TL1A playing in the IBD space? And... there does seem to be more discussions about combination therapy as maybe the next step for the market."
— Chris Schott, JPMorgan

A: "Our hope is tulisokibart could be one of the first and best-in-class TL1As... from an AE profile, I might describe it as a kinder gentler AE profile than other [anti-]TNFs and with profound efficacy. So I think combinations will be [emerging]." — Dr. Dean Li, President, MRL

Assessment: A clean tolerability profile is exactly what makes a molecule a combination backbone, which is where IBD is heading. The ATLAS-UC readout is the gating event that determines whether TL1A becomes a franchise or a footnote.

What They're NOT Saying

1. No quantified pipeline read-through from LITESPARK-012. Management asserts no implication for the June and October WELIREG decisions but offers no probability framing, leaving investors to take the "no read-through" claim on faith into the next PDUFA.
2. Terns not in the guide. A material pending acquisition with a ~$2.35/share charge is excluded from the outlook, so the "raised" guidance is not the number that will actually be reported once Terns closes in May.
3. Net-debt trajectory unaddressed. With Cidara and Terns pushing net debt toward ~$50B, management reiterated investment-grade capacity but did not frame a leverage ceiling or how much dry powder remains for the next "bigger" deal it keeps flagging.
4. No fresh Keytruda erosion math. Despite Qlex progress, management again declined to pair the 30–40% conversion target with an assumed IV Keytruda decline curve, so the net post-2028 hole remains unquantified.
5. Q3 Keytruda headwind flagged but not sized precisely. The ~$250M Q1 purchase-timing benefit reverses in Q3, but management did not detail the net quarterly cadence, complicating half-by-half modeling.
6. Reorg disruption risk downplayed. A commercial reorganization into new business units mid-transition was framed entirely as upside, with no discussion of execution or attrition risk during a period of 20-plus concurrent launches.

Market Reaction

• Pre-print setup: MRK closed at $110.95 the day before the print, having pulled back ~7.8% over the prior 30 days from a 52-week closing high of $123.93 (reached after our February initiation). The stock was up 5.4% YTD and 30.2% over the trailing 12 months, so it entered with a re-rated base but softening momentum.
• Reaction (BMO, same-day session): Shares gapped down ~1.5% at the open and closed -1.6% at $109.18 on ~17.1M shares (1.8x the 30-day average), while the S&P 500 rose 1.0% on the day.

This was a "good quarter, tired stock" reaction. The beat and guide raise were real, but the market fixated on the lower-quality elements: the Keytruda beat flattered by ~$250M of Q1 purchase timing that reverses in Q3, the LITESPARK-012 failure the prior week, and yet another charge-generating acquisition. With the stock already up ~30% over the trailing year and sitting off its highs, there was little appetite to pay up for an operationally strong but optically messy print. That the stock underperformed a rising tape by ~2.6 points reflects positioning fatigue more than any fundamental deterioration.

Street Perspective

Debate: Is the Pipeline Actually De-Risking, or Just Getting More Expensive?

Bull view: IDVYNSO approved, enlicitide and Winrevair data positive at ACC, Qlex ramping with its J-code, and a dense run of PDUFAs from June through October give a clear, catalyst-rich de-risking path toward the $70B.

Bear view: LITESPARK-012 just failed, the pipeline is being padded with serial acquisitions that add debt and charges rather than proven revenue, and no single asset rivals Keytruda's scale.

Our take: Both moved this quarter, roughly canceling out. The internal launches (Winrevair, enlicitide, IDVYNSO) are genuinely de-risking; the acquired pipeline is optionality bought with the balance sheet. Net, the pillar is intact but no stronger, which is why our rating did not change.

Debate: Is the Serial M&A Discipline or Empire-Building?

Bull view: Every deal (Verona, Cidara, Terns) fits the $1–15B science-first framework, adds a credible growth driver, and leaves leverage manageable at ~1.45x EBITDA.

Bear view: Three upfront-charge deals in two quarters, net debt heading to ~$50B, and a CEO who says he "can always do better" points to acquisition momentum that could culminate in a dilutive mega-deal at the wrong time.

Our take: The individual deals are defensible and the leverage is still fine, but the cadence has become a genuine watch item. The buyback and the willingness to "go bigger" cannot both scale indefinitely; capital-allocation discipline is now something to verify, not assume.

Debate: Cheap-for-a-Reason or Mispriced?

Bull view: ~12x underlying forward earnings, a 3% dividend, Keytruda still growing double digits, and a deep catalyst calendar make MRK a rare value name in large-cap pharma.

Bear view: The low multiple is the market correctly pricing a 2028/2029 earnings air-pocket that the pipeline may not fully fill dollar-for-dollar, and it can compress further as the cliff nears.

Our take: Unchanged from our initiation: fair, not cheap enough to force the issue. The valuation limits downside and the cliff caps upside, leaving a market-like return profile that argues for patience over conviction in either direction.

Model Update Needed

Valuation impact: At $109.18, MRK trades at ~12–13x underlying (ex-one-time-charge) 2026 EPS of ~$8.7–9.0 and yields ~3%. We hold our fair-value range at roughly $108–125; the ~6% pullback since our February initiation nudges the risk/reward marginally more favorable but leaves the stock inside our range, implying a market-like total return. No change to target framework; the LITESPARK-012 removal of a WELIREG upside case is offset by the Winrevair HFpEF option and the Qlex/IDVYNSO progress.

Thesis Scorecard Post-Earnings

Overall: Thesis unchanged. The launch and Keytruda pillars strengthened, the valuation and no-growth points are roughly where they were, and the pipeline pillar took a modest hit from LITESPARK-012 while gaining from IDVYNSO/Qlex. The net is a wash, which is precisely why the rating holds. Management met last quarter's commitments, but the emergence of a Phase 3 failure and a third upfront-charge deal keeps the balance even.

Action: Maintain Hold. Own it for the dividend, the cheap multiple, and the catalyst-rich calendar (June ASCO event, June/August/October PDUFAs), but wait for the pipeline to prove it can fill the hole or for a lower entry before pressing. We would upgrade on a clean run of the mid-year PDUFAs plus evidence of accelerating Qlex conversion; we would downgrade on further Phase 3 failures, a dilutive mega-deal, or a leverage step-up beyond investment-grade comfort.